(VIANEWS) – The NASDAQ ended the session with Inovio Pharmaceuticals (INO) rising 6.02% to $1.76 on Tuesday while NASDAQ rose 0.25% to $10,829.50.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-associated diseases, such as cervical, vulvar and anal dysplasia. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, The Wistar Institute of Research, Thermo Fisher Military Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, Thermo Fisher Research, and Thermo Fisher to support the Wistar Institute of Research, Thermo Fisher and Thermo Fisher and Thermo Fisher a Fisher Scientific, Thermo Fisher Research, Thermo Fischer Thermo Fishinger, and Thero Fisher To support the investigational DNA vaccine, INO-4800 for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.

Return on Equity (TTM)

Inovio Pharmaceuticals’s ROE is -70.1%.


Today’s last reported volume for Inovio Pharmaceuticals is 4360370, 25.47% below its average volume of 5850500.

Inovio Pharmaceuticals’s last close was $1.66, 78.99% under its 52-week high of $7.90.

Inovio Pharmaceuticals’s Sales

Inovio Pharmaceuticals’s sales growth is 90.5% for the current quarter and a decline by 45.4% for the next. The company’s growth estimates for the ongoing quarter and the next is 20.5% and 3.4%, respectively.

Inovio Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth declined by 46.4%, now sitting on 1.6M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).

Inovio Pharmaceuticals’s Stock Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $1.76 at 18:30 EST, way below its 52-week high of $7.90 and way above its 52-week low of $1.38.

Inovio Pharmaceuticals’s Moving Average

Inovio Pharmaceuticals’s value is way under its 50-day moving average of $2.19 and way under its 200-day moving average of $3.03.

More news about Inovio Pharmaceuticals (INO).


Please enter your comment!
Please enter your name here